Henry Schein, Inc.

HSIC Healthcare · Medical Distribution
Delayed 15 min
Last close
$86.99
Oct 16, 2026
52-week range
$62.05 — $92.18
-6% from high
Market cap
9.7B
Diluted basis
Dividend yield
—
No dividend declared
P/E
25.4
Trailing
Verdict status · Oct 16, 2026

Not yet scored

Filing.fyi has not computed forensic scores for HSIC yet. Scores appear after the company's next data refresh.

No verdict yet
RED DEEP Scores pending shown after the next data refresh
Composite Health
AI synthesis · written from this company's SEC filings · not investment advice

What the filing actually says.

AI · forensic preset

The filings show a company growing its top line while its quarterly earnings and cash generation have not kept pace. Annual revenue rose from $12.67 billion in 2024 to $13.18 billion in 2025, an increase of about 4.0%, and the first quarter of 2026 extended that trend with net sales of $3,368 million. The growth is spread across the three reportable segments. Global Distribution and Value-Added Services, which made up 84.3% of quarterly sales, grew 6.1%, with Global Dental Merchandise, Global Dental Equipment, and Global Medical all contributing. Global Specialty Products, which the filing says carries higher gross margins because it includes products the company develops and manufactures, rose 8.1% to $397 million. Global Technology, which provides practice management software, grew 7.0% to $173 million. Those segment details are the strongest part of the story. The weaker part is what happened below gross profit. Operating expenses rose 7.8% to $888 million, faster than sales, and the filing lists $13 million of shareholder advisory and value creation consulting costs against $8 million a year earlier. Restructuring charges fell to $12 million from $25 million, but the 2024 Plan is not expected to finish until the end of 2027, and management has not determined the amount for 2026 through 2027. Readers may want to look at how much of the lower restructuring cost reflects timing rather than a lasting change. No forensic scores are in the data for this company, so this synthesis does not assess them. No news headlines were available either, so the analysis rests entirely on the filing text provided.

Catalyst.Management attributes the quarter's growth to several sources. Net sales for the three months ended March 28, 2026 rose to $3,368 million from $3,168 million, up 6.3%, with internal growth of 2.5%, acquisitions adding 0.7%, and foreign exchange adding 3.1%. Global Dental Merchandise led the increase, rising 9.0% to $1,292 million, and Global Technology grew 7.0%, which the MD&A ties primarily to adoption of its cloud-based practice management platforms. Gross profit reached $1,070 million, up from $1,000 million, and operating income was $182 million compared with $175 million a year earlier.

Hidden risk.The 6.3% headline growth overstates the local business picture. Foreign exchange contributed 3.1 percentage points, about half of the total increase. Net income attributable to Henry Schein, Inc. fell to $107 million from $110 million even as sales rose. Operating cash flow was negative $97 million for the quarter, compared with positive $37 million a year earlier. The MD&A excerpt does not explain the drivers of that cash outflow, so readers may want to look at the full cash flow statement. Restructuring under the 2024 Plan is expected to run through the end of 2027, and management has not yet determined the amount of charges for 2026 through 2027.

Market signals · from trading data, not filings

What traders are betting.

The scores above come from what HSIC reports to the SEC. These readings come from how traders are positioned in its shares. They change quickly, they can be wrong, and they are not part of the verdict.
Short interest Shares sold short · reported twice a month
9.0%
of the shares available to trade
Moderate
0%5% · 10% · 20%25%+

The metric

Shares that traders have borrowed and sold, betting the price will fall, and not yet bought back. Brokers report the total to FINRA twice a month. Days to cover divides it by the shares that change hands on a typical day.

Shares sold short
8.3M
Change since Aug 31
+2.2%
Days to cover
7.5

What it tells us

A noticeable minority of traders is betting that HSIC shares will fall.

Little changed since the Aug 31 report (+2.2%).

Short sellers would need about 7.5 days of normal trading to buy back every borrowed share. A slow exit like that can make a rush to cover sharper.

How investors use it

  • Squeeze watching. Some aggressive traders seek out heavily shorted stocks, betting that good news will force short sellers to buy back shares and push the price higher.
  • Hedging. Funds short one company to offset risk in another, often owning a stronger business and shorting a weaker one in the same industry.
  • Timing. Chart-based traders pair rising short interest with price patterns, such as a break below a level where buyers used to step in, to decide when to enter or exit.
  • Warning sign. Some owners treat a sharp rise in short interest as a red flag and respond by tightening stop-loss orders or holding smaller positions.

Lesson: short interest, explained →

Short-interest report for Sep 30, 2026, via Yahoo Finance. Reports come out about a week and a half after that date.

SEC filings · last 12 months

Annual report, quarterly reports & proxy statement

The annual report (10-K), quarterly reports (10-Q), proxy statement (DEF 14A) and current reports (8-K) Henry Schein filed in the last 12 months, each linked to the original document on SEC EDGAR.

  • Oct 8, 2026
    8-K
    Current reportItem 5.02: Departure/appointment of officers or directors; Item 7.01: Regulation FD disclosure (investor materials)
    ★ Curriculum-relevant
    EDGAR →
  • Sep 22, 2026
    8-K
    Current reportItem 1.01: Signed a material agreement; Item 2.03: New debt or other financial obligation
    ★ Curriculum-relevant
    EDGAR →
  • Aug 4, 2026
    8-K
    Current reportItem 2.02: Results of operations (earnings)0
    EDGAR →
  • Aug 4, 2026
    10-Q
    Quarterly report0
    EDGAR →
  • Jul 30, 2026
    8-K
    Current reportItem 5.02: Departure/appointment of officers or directors; Item 7.01: Regulation FD disclosure (investor materials)
    ★ Curriculum-relevant
    EDGAR →
  • May 5, 2026
    10-Q
    Quarterly report (2026-03-28)Period: 2026-03-280
    EDGAR →
  • May 5, 2026
    8-K
    Current report (2026-05-05)Item 2.02: Results of operations (earnings)0
    EDGAR →
  • Apr 8, 2026
    DEF 14A
    Proxy statement (2026-05-21)0
    EDGAR →
  • Feb 24, 2026
    8-K
    Current report (2026-02-24)Item 2.02: Results of operations (earnings)0
    EDGAR →
  • Feb 24, 2026
    10-K
    Annual report (2025-12-27)Period: 2025-12-270
    EDGAR →
  • Jan 12, 2026
    8-K
    Current report (2026-01-09)No specific items found in 8-K.0
    EDGAR →
Further reading · curated for this filing

If this case caught your eye

Affiliate links — Filing.fyi earns a commission on Amazon purchases. We pick the books first, attach the link second.

Financial Shenanigans

Howard M. Schilit

Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.

View on Amazon →

The Interpretation of Financial Statements

Benjamin Graham

The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.

View on Amazon →

Quality of Earnings

Thornton L. O'glove

Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.

View on Amazon →